TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
*
Home
Industry Press release
Medicine Press release
Olympus Launches New Surgical Energy Device for Hemostatic Cutting and Vessel Sealing
Oct 21, 2025 22:00 JST
Olympus Corporation (Olympus), a global MedTech company committed to making people's lives healthier, safer and more fulfilling, today announced the launch of THUNDERBEAT II, the next generation hybrid energy device for soft tissue management, designed to deliver faster, more hemostatic dissection and large vessel transection[1] in both laparoscopic and open surgery.
More info..
Olympus Launches New Surgical Energy Device for Hemostatic Cutting and Vessel Sealing
Oct 21, 2025 22:00 JST
Olympus Corporation (Olympus), a global MedTech company committed to making people's lives healthier, safer and more fulfilling, today announced the launch of THUNDERBEAT II, the next generation hybrid energy device for soft tissue management, designed to deliver faster, more hemostatic dissection and large vessel transection[1] in both laparoscopic and open surgery.
More info..
Indonesia's Legacy in the Global Vaccine Landscape: Bio Farma and DCVMN Strengthen Health Resilience through Global Partnership
Oct 21, 2025 15:45 JST
Through PT Bio Farma (Persero), Indonesia has played a strategic and sustained role in the Developing Countries Vaccine Manufacturers' Network (DCVMN), working to ensure equitable access to safe, high-quality, and affordable vaccines.
More info..
Indonesia's Legacy in the Global Vaccine Landscape: Bio Farma and DCVMN Strengthen Health Resilience through Global Partnership
Oct 21, 2025 15:45 JST
Through PT Bio Farma (Persero), Indonesia has played a strategic and sustained role in the Developing Countries Vaccine Manufacturers' Network (DCVMN), working to ensure equitable access to safe, high-quality, and affordable vaccines.
More info..
Olympus: "Feasibility study on the development of Japanese digitalized endoscopy infection control systems in India" Selected for METI's FY2024 Supplementary "Global South Future-Oriented Co-Creation Subsidy Program (Small-Scale Demonstration / Feasibility Study Project)"
Oct 21, 2025 10:00 JST
Olympus Corporation (Olympus), today announced that the feasibility study project entitled "Feasibility study on the development of Japanese digitalized endoscopy infection control systems in India," jointly proposed with Saraya Co., Ltd. (hereinafter "SARAYA"), has been selected by the Ministry of Economy, Trade and Industry (METI) under its FY2024 supplementary "Global South Future-Oriented Co-Creation Subsidy Program (Small-Scale Demonstration/Feasibility Study Project)" on August 1, 2025.
More info..
Olympus: "Feasibility study on the development of Japanese digitalized endoscopy infection control systems in India" Selected for METI's FY2024 Supplementary "Global South Future-Oriented Co-Creation Subsidy Program (Small-Scale Demonstration / Feasibility Study Project)"
Oct 21, 2025 10:00 JST
Olympus Corporation (Olympus), today announced that the feasibility study project entitled "Feasibility study on the development of Japanese digitalized endoscopy infection control systems in India," jointly proposed with Saraya Co., Ltd. (hereinafter "SARAYA"), has been selected by the Ministry of Economy, Trade and Industry (METI) under its FY2024 supplementary "Global South Future-Oriented Co-Creation Subsidy Program (Small-Scale Demonstration/Feasibility Study Project)" on August 1, 2025.
More info..
LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025"
Oct 14, 2025 16:54 JST
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that LEQEMBI(R) IQLIK(TM), a subcutaneous autoinjector formulation of lecanemab (generic name), for the treatment of Alzheimer's disease (AD) has been selected by TIME as one of the "Best Inventions of 2025" in the Medical and Healthcare category.
More info..
LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025"
Oct 14, 2025 16:54 JST
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that LEQEMBI(R) IQLIK(TM), a subcutaneous autoinjector formulation of lecanemab (generic name), for the treatment of Alzheimer's disease (AD) has been selected by TIME as one of the "Best Inventions of 2025" in the Medical and Healthcare category.
More info..
Eisai and Biogen Announce U.S. Availability of LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
Oct 08, 2025 11:03 JST
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that lecanemab-irmb subcutaneous injection (U.S. brand name: LEQEMBI(R) IQLIK(TM) is now available in the U.S. as a maintenance dosing regimen for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD).
More info..
Eisai and Biogen Announce U.S. Availability of LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
Oct 08, 2025 11:03 JST
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that lecanemab-irmb subcutaneous injection (U.S. brand name: LEQEMBI(R) IQLIK(TM) is now available in the U.S. as a maintenance dosing regimen for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD).
More info..
1
2
3
>>
Last
Releases By Industry
Business
Communications
CryptoCurrency
Financial
Industrial
Lifestyle
Medicine
Sustainablity
Technology